A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
A randomized, double-blind, superiority, multiple dose, placebo-controlled, parallel group, multi-centre, field study.
A minimum of 1182 subjects will be randomized into the study, 394 in each of 2 active treatment groups and placebo group, at a ratio of 1:1:1. Subjects will be stratified in each of the treatment groups according to asthma status and according to age, such that a target of 20%-30% of subjects are adolescent (12-17 years) and 70%-80% of subjects are adults (18-65 years). Subjects who withdraw may be replaced.
Subjects aged 12-65 years, with a documented history of moderate to severe allergic rhinoconjunctivitis only or allergic rhinoconjunctivitis plus GINA Step 1 controlled asthma on exposure to cats for at least 2 years.
| Condition | Allergy |
|---|---|
| Clinical Study Identifier | TX137586 |
| Sponsor | Circassia Ltd. |
| Last Modified on | 21 April 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.